The agency has set a Prescription Drug User Fee Act (PDUFA) target action date of December 16, 2023. Roflumilast is a once-daily, topical phosphodiesterase type 4 (PDE4) inhibitor under development for the treatment of inflammatory dermatoses, focusing on the hair-bearing areas including the face, scalp, and trunk.